

10th February, 2009

PHARMACY CHAIN 36,6 ANNOUNCES 2008 PRELIMINARY RESULTS (UNAUDITED)

February 10, 2009, MOSCOW – OJSC Pharmacy Chain 36.6 [RTS:APTK; MICEX:RU14APTK1007] the leading Russian pharmaceutical retailer announces unaudited sales and operational results according to the management accounts.

GROUP SALES¹:

- Y-O-Y Group's consolidated sales increased by 21,6% and reached US\$ 1 058,9 million.
- Y-O-Y Pharmacy Retail Sales grew by 24,9% and reached US\$ 840,8 million.
- Y-O-Y Sales of the production unit Veropharm grew by 23,0% and reached US\$ 171,6 million.
- Y-O-Y Sales of Early Learning Center grew by 90% to \$5.7 million.
- Y-O-Y other non-core businesses declined by 26,1% as the Company no longer consolidates the operation of European Medical Center.

<i>USD mln</i>	Consolidated	Retail	Veropharm	ELC	Other
2008	1 058,9	840,8	171,6	5,7	40,8
2007	871,1	673,4	139,5	3,0	55,2
<i>Change y-o-y</i>	<i>21,6%</i>	<i>24,9%</i>	<i>23,0%</i>	<i>90%</i>	<i>-26,1%</i>

Jere Calmes, President and CEO of Pharmacy Chain 36.6:

"Our preliminary 2008 results show some important achievements. Despite the difficult Q4 downturn, we managed full year growth of over 21% in both our pharmaceutical retail and manufacturing units. We have significantly reduced our financial debt and made a solid breakthrough in our retail chain private label program. Nevertheless, the difficult economic and financing environment continues to present challenges for our business going forward. We will continue to work with our Board of Directors to resolve the funding issues while focusing on cost reduction in the operations and value propositions for our customers".

RETAIL:

- As of the end of 2008 Pharmacy Chain 36.6 operated 1127 stores in 29 regions of Russia.
- During 2008 86 stores were opened organically and 183 were closed. In Q4 19 stores were opened and 60 stores were closed. During 2008, 12 stores were rebranded and 3 reformatted (in Q4 no stores were rebranded or reformatted).
- As of the end of 2008 Pharmacy Chain 36.6 operated 11 ELC stores, 14 stand-alone optical outlets and 21 additional optical departments within pharmacies.

¹ Hereinafter – these financial indicators may vary from the consolidated financial reporting prepared in accordance with IFRS.

As of 31.12.2008

Business Unit²	No. of pharmacies	Share of Sales	Ave. retail space per pharmacy, sq.m.
1. Moscow-Central	385	43,2%	73.7
<i>Northwest</i>	<i>26</i>	<i>2,74%</i>	<i>67.2</i>
2. South Urals	250	17,4%	57.1
3. South	196	16,7%	50.2
4. Volga	128	9,0%	61.2
5. North Urals	101	9,2%	54.0
6. Siberia	67	4,5%	53.4
Company Total:	1127	100%	61.5

OPERATIONAL DATA FOR THE RETAIL UNIT:

- During 2008 101,3 million purchases were made in Pharmacy Chain 36.6, which is 11,8 % higher than in 2007. In Q4 2008 23,9 million purchases were made which is 9,4 % less than in comparable period of 2007.
- In 2008 average check across the network reached US\$ 8.46, in Moscow - US\$ 12.0, an increase over 2007 15.1% and 11.1% respectively. In Q4 2008 average check across the network reached US\$ 8,26, in Moscow – US\$ 11,5, an increase over comparable period of 2007 5,5% and 1% respectively.
- Average sales floor size at the end of 2008 is 61.5 sq meters, an increase of 1,2 % versus 2007.

PRIVATE LABEL:

- In 2008 the private label sales reached US\$ 34,8 million which represents 299.5% growth compared to 2007.
- In 2008 the share of private label sales reached 4,1% as compared to 1,3% in 2007.
- The number of SKUs has increased by 118,8% from 319 at the end of 2007 to 698 by the end of 2008.

LIKE-FOR-LIKE SALES IN COMPARABLE STORES³:

As of the end of 2008 the Company operates 603 comparable stores representing 61% of sales and 57% of traffic in the retail unit in 2008.

L-F-L sales growth in these stores reached 10% as compared to 2007 while traffic decreased by 8%:

Business unit	Number of comparable stores	L-F-L sales growth USD	Average check growth, USD
1.Moscow-Central	224	14%	15%
<i>Northwest</i>	<i>20</i>	<i>32%</i>	<i>29%</i>
2.South Urals	166	5%	22%
3.South	80	8%	28%
4.Volga	85	7%	21%
5.North Urals	36	10%	18%
6.Siberia	12	18%	33%
Total:	603	10%	21%

² Due to organizational changes Northwest is now managed by Moscow-Central. In addition, Urals is broken into two units: North Urals and South Urals.

³ Comparable stores are defined as stores:

- Opened or acquired 24 months from the current reporting period, and
- Neither rebranded nor reformatted or significantly changed during the last 24 months, and
- Not closed in the current reporting period.

L-F-L sales in Q4 2008 decreased by 10 % as compared to Q4 2007 driven by the foreign exchange effect of rouble depreciation and the very challenging economic environment (in rouble terms the L-F-L sales in Q 4 2008 remained at the same level as compared to Q4 2007). Traffic decreased by 15% in Q4 2008 as compared to Q4 2007.

Business unit	Number of comparable stores	L-F-L sales growth USD	Average check growth, USD
1.Moscow-Central	224	-3%	1%
<i>Northwest</i>	<i>20</i>	<i>5%</i>	<i>9%</i>
2.South Urals	166	-17%	4%
3.South	80	-13%	22%
4.Volga	85	-16%	4%
5.North Urals	36	-19%	-2%
6.Siberia	12	-2%	14%
Total:	603	-10%	8%

DEBT:

As of the end of 2008, the total Group's financial debt (the principal amount) reached US\$ 150,5 million, including debt of Veropharm US\$ 21,3 million.

#

For further information please refer to:

Dmitry Anisimov

Chief Financial Officer

Management company «Pharmacy Chain 36,6»

anisimov.d@366.ru

tel. (+7 495) 797 86 87

Irina Lavrova

Director, Corporate communications

Management company «Pharmacy Chain 36,6»

lavrova.i.n@366.ru

tel. (+7 495) 797 86 86

ext.12-10

Natalia Kharchevnikova

IR Manager

Management company «Pharmacy Chain 36,6»

kharchevnikova.n.g@366.ru

tel. (+7 495) 797 86 81

ext.17-63

Or to the web-site of the company:

www.pharmacychain366.ru

ir@oao366.ru

Notes to the editor:

Pharmacy Chain 36.6 is the first public national health and beauty retailer listed on the "B" list on the RTS (ticker: APTK) and off-list on the MICEX. The Company's market capitalization as of January 30, 2009 totaled USD 10,5 million (according to RTS). Pharmacy Chain 36.6 operates more than 1100 stores in 29 regions and 90 cities in Russia.

OAO Veropharm, the company's generics subsidiary, is one of Russia's top five pharmaceutical manufacturers (according to Pharmexpert research). Veropharm's shares are traded in the "B" list on the RTS (ticker: VRPH) and off-list on MICEX (ticker: VRFM). OAO Veropharm's market capitalization as January 30, 2009 was USD 100 million (according to RTS).

ZAO Apteki 36.6 is one of the founding members of the Russian Association of Pharmacy Chains (RAPC). Pharmacy Chain 36.6 and its subsidiaries employ over 9 800 people.

THIS DOCUMENT IS NOT AN ADVERTISEMENT OF SECURITIES IN THE RUSSIAN FEDERATION AND IS NOT AN OFFER TO SELL OR AN INVITATION TO MAKE OFFERS TO PURCHASE ANY SECURITIES IN THE RUSSIAN FEDERATION.

NOT FOR RELEASE DIRECTLY OR INDIRECTLY IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.

This document should not be considered a public offering of securities in the United States. Any securities referred to herein have not been and will not be registered under the US Securities Act of 1933 as amended (the "Securities Act") and may not be offered or sold in the United States or to US persons.

This communication is being distributed only to and is directed only at (a) persons outside the United Kingdom and (b) persons in the United Kingdom who have (i) professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 (the "Order") or (ii) high net worth companies and other bodies to whom it may otherwise lawfully be communicated in accordance with Article 49(2) of the Order (all such persons specified in clauses (a) and (b) and together being referred to as "relevant persons"). Any securities referred to in this press release and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be available only to or will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.